Injectable HAMA-CPC hydrogels loaded with high-yield 3D bioprinted adipose-derived stem cell small extracellular vesicles for increased bone repair.
Xu W., Gao W., Zhang Y., Hou G., Zhang W., Deng J.
Animal Study, published in J Nanobiotechnology (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- J Nanobiotechnology (2025)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40685362
- PMCID
- PMC12278526
- DOI
- 10.1186/s12951-025-03596-4
- Citations
- 1
Abstract (original English)
In the field of bone tissue engineering, the development of effective strategies for bone defect repair remains a major challenge. Herein, we report a novel approach involving the integration of high-yield 3D bioprinted adipose-derived stem cell small extracellular vesicles (3D-sEVs) into an injectable HAMA-CPC hydrogel (HAMA-CPC@3D-sEVs). In vitro, HAMA-CPC@3D-sEVs significantly promoted the proliferation, migration, and osteogenic differentiation of bone marrow stromal cells (BMSCs) and promoted angiogenesis in human umbilical vein endothelial cells (HUVECs). In vivo, in a rat tibial defect model, this treatment strongly promoted bone regeneration, increasing the bone volume fraction (BV/TV), bone volume (BV), and trabecular thickness (Tb.Th) at 4 weeks post-surgery. Mechanistically, proteomic analysis revealed that NAMPT in 3D-sEVs upregulated S1PR1 in HUVECs, leading to increased VEGF expression and angiogenesis. These findings suggest that 3D-sEVs-functionalized HAMA-CPC hydrogels have good potential for bone defect repair.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.